Study: Treating "low T" could have high risks

Share this article:

Men undergoing testosterone therapy are at an increased risk for heart attack and stroke, research suggests. Bloomberg reports that the study also found a 29% increase in death, based on an assessment of 8,709 men in the US Veterans Affairs health system.

JAMA Associate Editor Anne Cappola told Bloomberg that the study reveals two things: that patients need to understand the risks, and that the marketing surrounding the treatments should be scrutinized.

The findings could have implications for drugs such as AbbVie's AndroGel and Eli Lilly's Axiron. These prescription meds are part of a market Bloomberg pegs at around $1.6 billion.

This VA study is not the first to take on testosterone. Bloomberg notes that the National Institute on Aging stopped a 2000 study over an increased heart attack risk and high blood pressure.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.